TrialHepatology international2017

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.

Mark S Sulkowski et al.PubMed ↗Publisher ↗

No numbers read from the abstract.